Search for other papers by Lars C. Moeller in
Google Scholar
PubMed
Search for other papers by Yaw Appiagyei-Dankah in
Google Scholar
PubMed
Search for other papers by Birgit Köhler in
Google Scholar
PubMed
Search for other papers by Heike Biebermann in
Google Scholar
PubMed
Search for other papers by Onno E. Janssen in
Google Scholar
PubMed
Search for other papers by Dagmar Führer in
Google Scholar
PubMed
Introduction In serum, thyroid hormone (TH) is mainly bound to transport proteins. The major proportion of circulating TH, 75% of T 4 and 70% of T 3 is bound to thyroxine-binding globulin [TBG; HUGO Gene Nomenclature Committee approved name
Search for other papers by Kevin Stroek in
Google Scholar
PubMed
Endocrine Laboratory, Department of Clinical Chemistry, Amsterdam Gastroenterology, Endocrinology & Metabolism, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands
Search for other papers by Annemieke C. Heijboer in
Google Scholar
PubMed
Search for other papers by Marja van Veen-Sijne in
Google Scholar
PubMed
Search for other papers by Annet M. Bosch in
Google Scholar
PubMed
Search for other papers by Catharina P.B. van der Ploeg in
Google Scholar
PubMed
Search for other papers by Nitash Zwaveling-Soonawala in
Google Scholar
PubMed
Search for other papers by Robert de Jonge in
Google Scholar
PubMed
Search for other papers by A.S. Paul van Trotsenburg in
Google Scholar
PubMed
Search for other papers by Anita Boelen in
Google Scholar
PubMed
concentrations, and in order to detect CH-C, thyroxine-binding globulin (TBG) is measured in the lowest 5% of T4 concentrations enabling calculation of a modified T4/TBG ratio that serves as an indirect measure of free T4 (FT4). With this approach, low T4 values
Search for other papers by Hiroyuki Iwaki in
Google Scholar
PubMed
Search for other papers by Kenji Ohba in
Google Scholar
PubMed
Search for other papers by Eisaku Okada in
Google Scholar
PubMed
Search for other papers by Takeshi Murakoshi in
Google Scholar
PubMed
Search for other papers by Yumiko Kashiwabara in
Google Scholar
PubMed
Search for other papers by Chiga Hayashi in
Google Scholar
PubMed
Search for other papers by Akio Matsushita in
Google Scholar
PubMed
Search for other papers by Shigekazu Sasaki in
Google Scholar
PubMed
Search for other papers by Takafumi Suda in
Google Scholar
PubMed
Search for other papers by Yutaka Oki in
Google Scholar
PubMed
Search for other papers by Rieko Gemma in
Google Scholar
PubMed
dosage that ensures maternal serum free thyroxine (FT4) levels at or moderately above the upper limit of the reference range is reported to be appropriate for fetal euthyroid status [ 2 ]. This recommendation was incorporated into the 2017 American
Departments of Vascular Medicine, University of Amsterdam, Amsterdam
Search for other papers by Laura P.B. Elbers in
Google Scholar
PubMed
Search for other papers by Hjalmar A. Boon in
Google Scholar
PubMed
Search for other papers by Maaike I. Moes in
Google Scholar
PubMed
Departments of Vascular Medicine, University of Amsterdam, Amsterdam
Search for other papers by Bregje van Zaane in
Google Scholar
PubMed
Departments of Vascular Medicine, University of Amsterdam, Amsterdam
Search for other papers by Dees P.M. Brandjes in
Google Scholar
PubMed
Search for other papers by Eric Fliers in
Google Scholar
PubMed
Search for other papers by Harry R. Büller in
Google Scholar
PubMed
Einthoven Laboratory for Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands
Search for other papers by Suzanne Cannegieter in
Google Scholar
PubMed
Departments of Vascular Medicine, University of Amsterdam, Amsterdam
Search for other papers by Victor E.A. Gerdes in
Google Scholar
PubMed
thromboembolism (VTE) or bleeding. Higher plasma levels of free thyroxine (FT 4 ) have been associated with an increased VTE risk [ 1 , 2 , 3 ]. Conversely, lower levels of FT 4 seem to be associated with a bleeding tendency [ 4 , 5 ]. An observational cohort
Search for other papers by Ladan Mehran in
Google Scholar
PubMed
Search for other papers by Atieh Amouzegar in
Google Scholar
PubMed
Search for other papers by Hengameh Abdi in
Google Scholar
PubMed
Search for other papers by Negar Delbari in
Google Scholar
PubMed
Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
Search for other papers by Elham Madreseh in
Google Scholar
PubMed
Search for other papers by Maryam Tohidi in
Google Scholar
PubMed
Search for other papers by Mohammad Ali Mansournia in
Google Scholar
PubMed
Search for other papers by Fereidoun Azizi in
Google Scholar
PubMed
. 2009 Jan 25 ; 10 : 5 http://dx.doi.org/10.1186/1745-6215-10-5 . 17 Amouzegar A , Delshad H , Mehran L , Tohidi M , Khafaji F , Azizi F . Reference limit of thyrotropin (TSH) and free thyroxine (FT4) in thyroperoxidase positive
Search for other papers by Sangeetha Sirigiri in
Google Scholar
PubMed
Search for other papers by Suresh Vaikkakara in
Google Scholar
PubMed
Search for other papers by Alok Sachan in
Google Scholar
PubMed
Search for other papers by P.V.L.N. Srinivasarao in
Google Scholar
PubMed
Search for other papers by Sunil Epuri in
Google Scholar
PubMed
Search for other papers by Sailaja Anantarapu in
Google Scholar
PubMed
Search for other papers by Arun Mukka in
Google Scholar
PubMed
Search for other papers by Srinivasa Rao Chokkapu in
Google Scholar
PubMed
Search for other papers by Ashok Venkatanarasu in
Google Scholar
PubMed
Search for other papers by Ravi Poojari in
Google Scholar
PubMed
elevated low-density lipoproteins and triglycerides [ 5 ]. Adequate treatment with thyroxine (T 4 ) is reported to improve both the insulin resistance as well as the dyslipidemia [ 5 , 6 ]. Abnormal body composition in the form of an increase in the
Search for other papers by Wilmar M. Wiersinga in
Google Scholar
PubMed
Search for other papers by Leonidas Duntas in
Google Scholar
PubMed
Search for other papers by Valentin Fadeyev in
Google Scholar
PubMed
Search for other papers by Birte Nygaard in
Google Scholar
PubMed
Search for other papers by Mark P.J. Vanderpump in
Google Scholar
PubMed
thyroid hormones by the thyroid gland. Thyroxine (T4) is produced exclusively by the thyroid gland; its daily production rate is about 100 µg at an average body surface area of 1.79 m 2 (56.2 µg/day/m 2 ). Daily production rate of triiodothyronine (T3
Search for other papers by P. Reed Larsen in
Google Scholar
PubMed
Search for other papers by Ann Marie Zavacki in
Google Scholar
PubMed
Introduction When dietary iodine is sufficient, the major product of the thyroid gland is thyroxine (T4) which is secreted at a rate of 10-fold that of 3,5,3′-triiodothyronine (T3) in humans. Thus, a rate-limiting step in thyroid hormone
Search for other papers by Selwan Khamisi in
Google Scholar
PubMed
Search for other papers by Peter Lindgren in
Google Scholar
PubMed
Search for other papers by F. Anders Karlsson in
Google Scholar
PubMed
/l (reference value 16.5 ± 5.3, mean ± SD [ 11 ]). Treatment with intra-amniotic injections of thyroxine was initiated and given in conjunction with ultrasound every 7-10 days with a dose 10 µg thyroxine/kg of estimated fetal weight per day on six occasions. The
Division of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan, Italy
Search for other papers by Luca Persani in
Google Scholar
PubMed
Search for other papers by Georg Brabant in
Google Scholar
PubMed
Search for other papers by Mehul Dattani in
Google Scholar
PubMed
Division of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan, Italy
Search for other papers by Marco Bonomi in
Google Scholar
PubMed
Search for other papers by Ulla Feldt-Rasmussen in
Google Scholar
PubMed
Search for other papers by Eric Fliers in
Google Scholar
PubMed
University Hospital Heidelberg, Heidelberg, Germany
Search for other papers by Annette Gruters in
Google Scholar
PubMed
Search for other papers by Dominique Maiter in
Google Scholar
PubMed
Search for other papers by Nadia Schoenmakers in
Google Scholar
PubMed
Search for other papers by A.S. Paul van Trotsenburg in
Google Scholar
PubMed
onset of treatment causes irreversible neurological defects. More frequently, diagnosis is made biochemically and should be suspected in every individual with low circulating free thyroxine (FT4) concentrations (free thyroxine index, FTI, can be a